APPLICATION OF RECOMBINANT HUMAN BRAIN NATRIURETIC PEPTIDE FOR PATIENTS WITH ACUTE MYOCARDIAL INFARCTION

Objective: The purpose of the study was to investigate the clinical effects of the application of recombinant human brain natriuretic peptide (rhBNP) for patients with acute myocardial infarction combined with occlusion of anterior descending branch after PCI at different time points. Methods: 50 patients with acute myocardial infarction combined with occlusion of anterior descending branch admitted to our hospital from March 2016 to March 2019 were selected as the study subjects. All patients were treated with PCI, and were randomly divided into observation group (n=25) and control group (n=25). The patients in the control group received rhBNP when they had the symptoms of heart failure, such as shortness of breath, echo, etc. after the intervention, while the patients in the observation group were treated with rhBNP immediately after the intervention. Cardiac function indicators at different time points were detected in both groups, and the levels of C-reactive protein (CRP) and N-terminal pro brain natriuretic peptide (NT-proBNP) and serum Troponin T (TnT) were were measured at different time points and compared between the two groups. Results: There were no significant differences in the levels of TnT, CRP, NT-proBNP and LVEDV at T1, T2 and T5 in the two groups (P > 0.05). The levels of TnT, CRP, NT-proBNP and LVEDV at T3 and T4 in the observation group were significantly lower than those in the control group (P < 0.05). There were no significant differences in the levels of LVEF and CO at T1, T2 and T5 in the two groups (P > 0.05), and the levels of LVEF and CO at T3 and T4 in the observation group were significantly higher than those in the control group (P < 0.05). Conclusion: In order to ensure the favourable prognosis of patients with acute myocardial infarction combined with occlusion of anterior descending branch after PCI, rhBNP therapy should be performed immediately after the intervention.